Allo Stim

GPTKB entity

Statements (50)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities stimulates immune response
enhances T cell activation
gptkbp:analyzes ongoing trials
post-transplant patients
gptkbp:appointed_by intravenous infusion
gptkbp:benefits enhanced anti-tumor activity
gptkbp:can_be_used_with other immunotherapies
gptkbp:clinical_trial gptkb:United_States
Phase 1
NCT number
pending publication
gptkbp:collaborations academic institutions
gptkbp:developed_by Allo Vir
gptkbp:dosage_form determined by clinical trial
gptkbp:duration varies by protocol
gptkbp:feedback collected during trials
gptkbp:frequency once per treatment cycle
gptkbp:future_plans exploring combination therapies
https://www.w3.org/2000/01/rdf-schema#label Allo Stim
gptkbp:indication hematologic malignancies
gptkbp:invention patented
gptkbp:investment gptkb:healthcare_organization
gptkbp:is_a_source_of human cells
gptkbp:is_monitored_by required during treatment
gptkbp:is_used_for treatment of cancer
gptkbp:manager systemic administration
gptkbp:market not commercially available
gptkbp:origin derived from donor cells
gptkbp:project clinical development
gptkbp:publishes peer-reviewed journals
gptkbp:receives_funding_from private investment
gptkbp:regulatory_compliance not yet approved
investigational new drug
gptkbp:research conducted in animal models
gptkbp:research_areas oncology
gptkbp:research_focus solid tumors
gptkbp:safety_features under evaluation
gptkbp:setting hospital or clinic
gptkbp:side_effect immune-related adverse events
monitored during trials
gptkbp:sponsor Allo Vir, Inc.
gptkbp:student_enrollment specific inclusion criteria
gptkbp:target_audience cancer patients
gptkbp:targets gptkb:T_cells
gptkbp:treatment improve survival rates
measured in trials
gptkbp:type gptkb:drug
gptkbp:bfsParent gptkb:Celularity_Inc.
gptkbp:bfsLayer 6